Regeneron's Schleifer touts Eylea's growth as he beats a forecast
This article was originally published in Scrip
Executive Summary
Leonard Schleifer earned a reputation as a CEO who under promises and over delivers. So when the Regeneron Pharmaceuticals chief says he sees a very large growth potential with his company’s eye drug Eylea, investors take note.
You may also be interested in...
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen's Scangos sees potential to dominate hemophilia market
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.